MPR1h
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
Zacks Investment Research on MSN3d
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...
Investor's Business Daily on MSN3d
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.
Zacks.com on MSN23h
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
STAT3d
Alnylam enters the ATTR-CM drug race
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ...
GlobalData on MSN3d
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.